Local immunomodulation around implants by innovative auxiliary hydrogel-based systems encapsulating autologous and phenotype controlled macrophages
The main objective of the European project Immodgel is to find innovative solutions to the frequent adverse immune reactions following implantation procedures. For this purpose, the consortium will create a personalised, immunomodulatory system that will be adjustable for any implant, medical device or transplant.
The adverse immune reactions against implants, biomedical devices and transplants will be reduced by means of an innovative system composed of physical, chemical (hydrogel) and biological (immune system cells) elements.
Furthermore, a diagnostic test will be developed to predict the patients´ specific immune responses to implant materials. The system´s chemical and physical properties will be modified accordingly to avoid implant rejection. Immodgel will for the first time allow implants to be personalised in order to minimise adverse immune reactions.
The key innovation will be the development of Immodgel as a system that will significantly decrease the level and duration of implant induced inflammation. In conjunction, optimising the healing process upon implantation is the second impact of the Immodgel system. Thus, it will reduce the negative outcomes of implant surgery, relieve pain and reduce related medical costs in Europe.
The collaborative research project Immodgel has started in October 2013 and will end in September 2017. It is co-financed by the European Commission with a funding of 5.85 million Euros.